COPYRIGHT© Jilin Zixin Pharmaceutical Industrial Co.,Ltd.

COPYRIGHT© 2018  吉林紫鑫药业股份有限公司

Jilin Zixin Pharmaceutical Co., Ltd. 2012 Annual Results Express

Page view

Stock code: 002118 Securities abbreviation: Zixin Pharmaceutical Announcement No.: 2013-006

Jilin Zixin Pharmaceutical Co., Ltd. 2012 Annual Results Express

 

The company and all members of the board of directors guarantee that the content of the information disclosure is true, accurate and complete, and there are no false records, misleading statements or major omissions.

    

Special Note: The financial data for 2012 in this announcement is only preliminary accounting data. It has been audited by the internal audit department of the company. It has not been audited by an accounting firm and may differ from the final data disclosed in the annual report. Investors should pay attention to investment risks.
 
 
I. Major financial data and indicators for 2012
 
 

unit: yuan

project

This reporting period

last year

Increase or decrease (%)

Total operating income

418,500,365.43

927,619,550.21

-54.88

operating profit

68,896,945.94

193,467,195.31

-64.39

The total profit

96,086,702.02

232,783,323.26

-58.72

Net profit attributable to shareholders of listed companies

88,306,201.12

217,289,950.92

-59.36

Basic earnings per share (yuan)

0.17

0.42

-59.52

Weighted average return on equity

4.76%

12.78%

-8.02

 

At the end of the reporting period

At the beginning of this report

Increase or decrease (%)

Total assets

3,049,320,863.72

2,789,164,038.40

9.33

Owner's equity attributable to shareholders of listed companies

1,897,428,653.67

1,809,088,719.21

4.88

Share capital

512,991,382.00

512,991,382.00

0.00

Net assets per share attributable to shareholders of listed companies (yuan)

3.70

3.53

4.82

 

Note: The above data is based on the company consolidated statement data.

2. Description of business performance and financial status

1. During the reporting period, the company achieved a total operating income of RMB 418,500,400, a decrease of 54.88% over the same period of the previous year. This was mainly due to the fact that the income of ginseng products decreased significantly compared with the same period of the previous year.

2. During the reporting period, the company realized operating profit of RMB 68,889,900, down 64.39% over the same period of the previous year; total profit was RMB 98,068,700, down by 58.72% over the same period of the previous year; net profit attributable to shareholders of listed company was RMB 88,306,200. In the same period of last year, it decreased by 59.36%; the basic earnings per share was 0.17 yuan, a decrease of 59.52% over the same period of the previous year. Mainly due to the sharp decline in operating income during the reporting period.

Third, the difference from the previous performance forecast

In the 2012 third quarterly report, the company's estimated operating results for 2012 are: net profit attributable to shareholders of listed companies decreased by 44.77%-58.58% from the same period of the previous year, with a range of RMB 90 million to RMB 120 million.

The operating results disclosed by the company's performance report were slightly lower than the previous performance forecast, which was reduced by 1,693,800 yuan, and the difference rate was 1.92%.

Fourth, the documents for reference

1. A comparative balance sheet and income statement signed and sealed by the current legal representative of the company, the person in charge of accounting work, and the person in charge of the accounting department;

2. Internal audit report signed by the head of the internal audit department.

Jilin Zixin Pharmaceutical Co., Ltd. Board of Directors

February 21, 2013